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and Werner Tegge1*Abstract
Background: Pathogenic serotypes of Vibrio cholerae cause the life-threatening diarrheal disease cholera. The increasing
development of bacterial resistances against the known antibiotics necessitates the search for new antimicrobial
compounds and targets for this pathogen.
Results: A high-throughput screening assay with a Vibrio cholerae reporter strain constitutively expressing green
fluorescent protein (GFP) was developed and applied in the investigation of the growth inhibitory effect of approximately
28,300 structurally diverse natural compounds and synthetic small molecules. Several compounds with activities in the
low micromolar concentration range were identified. The most active structure, designated vz0825, displayed a minimal
inhibitory concentration (MIC) of 1.6 μM and a minimal bactericidal concentration (MBC) of 3.2 μM against several strains
of V. cholerae and was specific for this pathogen. Mutants with reduced sensitivity against vz0825 were generated and
whole genome sequencing of 15 pooled mutants was carried out. Comparison with the genome of the wild type strain
identified the gene VC_A0531 (GenBank: AE003853.1) as the major site of single nucleotide polymorphisms in the resistant
mutants. VC_A0531 is located on the small chromosome of V. cholerae and encodes the osmosensitive K+-channel sensor
histidine kinase (KdpD). Nucleotide exchange of the major mutation site in the wild type strain confirmed the sensitive
phenotype.
Conclusion: The reporter strain MO10 pG13 was successfully used for the identification of new antibacterial compounds
against V. cholerae. Generation of resistant mutants and whole genome sequencing was carried out to identify the
histidine kinase KdpD as a novel antimicrobial target.
Keywords: Vibrio cholerae, Small molecules, Histidine kinase inhibitor, KdpD, whole genome sequencingBackground
Vibrio cholerae, a Gram-negative rod-shaped bacterium
belonging to the family Vibrionaceae, induces the acute
diarrheal disease cholera. Cholera has pandemic properties
and appears mainly in third world countries with esti-
mated 3–5 million cases and more than 100,000 deaths
per year [1]. The major pathogenic strains belong to the
serogroups O1 and O139. Infections are treated by oral or
intravenous rehydration therapy, which is complemented* Correspondence: nandy_rk@hotmail.com; werner.tegge@helmholtz-hzi.de
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reproduction in any medium, provided the orin severe cases with antibiotics to shorten the duration of
the clinical symptoms and to reduce the spreading. Long-
term and extensive use of antibiotics has led to resistance
development. A growing problem is the emergence of mul-
tidrug resistant pathogenic V. cholerae strains against which
therapeutic options are more and more limited [2]. Due to
this development the availability of novel therapeutic op-
tions is urgently needed.
In the present study we have developed a high-
throughput screening (HTS) assay that utilizes a V. cholerae
reporter strain constitutively expressing green fluorescence
protein and screened approximately 28,300 compounds
from six different chemical structural groups in a growth
inhibition assay. Several active molecules were identifiedl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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in vitro. V. cholerae mutants resistant to the most potent
molecule were generated. Whole-genome sequencing and
comparative analysis of the mutant to the wild type strain
was carried out. The apparent target of the most active
compound was identified to be the osmosensitive K+-chan-
nel sensor histidine kinase KdpD that apparently exerts cer-
tain essential function in this pathogen.
Results
HTS assay for inhibitors of V. cholerae viability
Green fluorescence producing plasmid pG13 was elec-
troporated into V. cholerae strain MO10 and the trans-
formants were selected on LB agar plates containing
kanamycin (Km, 30 μg/ml). Transfer of the plasmid
pG13 conferred green fluorescence phenotype in V. cho-
lerae O139 strain MO10. The screening assay was opti-
mized in 96- and 384-well microtiter plates (MTP). To
differentiate between active and non-active compounds
and as controls for the functionality of the assay, cipro-
floxacin (Cip, 100 μM) and dimethyl sulfoxide (DMSO,
1%) were included on each plate. DMSO had no growth
reducing effect at concentrations up to 1%. The evalu-
ation of the effect of compounds on the growth of strain
MO10 pG13 was carried out after 24 h of incubation,
with measurement of absorbance at 600 nm in combin-
ation with fluorescence determination (Figure 1). In theFigure 1 HTS assay. Growth of V. cholerae MO10 pG13 strain in 96- (A) an
(A): 12 A-B: 1% DMSO, 12C-D: 100 μM ciprofloxacin, 12 E-F: no addition of
23 E-H and 24 E-H: 100 μM ciprofloxacin, 23 J-M and 24 J-M: no addition o
absorbance at 600 nm; lower panels: fluorescence (485/535 nm). Wells framscreening campaigns of the six different substance col-
lections with 28,300 compounds in total, Z’-values be-
tween 0.5 and 0.9 with a mean of 0.8 were obtained,
which is an indication of a reliable performance of the
assay [3].
The six groups of screening compounds consisted of: i)
the commercially available LOPAC library (a collection of
pharmaceutically active compounds); ii) and iii) the EMC
(Echaz Microcollection) and CDI collections (Chemical
Diversity Lab), which contain small organic molecules that
were mainly generated by combinatorial synthesis; iv) the
VAR collection (various sources), which is unique at the
HZI and consists of small organic molecules that were
synthesized by cooperating chemists; v) the NCH collec-
tion (natural compounds), which is also unique at the HZI
and consists of purified secondary metabolites from myxo-
bacteria. It included potent agents with already known
antimicrobial or antiproliferative activity, e.g. epothilon,
which has been developed into a therapeutic agent against
breast cancer [4,5]; and finally vi) collections of linear and
cyclic peptides with a length of seven or eight D- or L-
amino acids were investigated [6]. The compounds were
used in one defined concentration between 20 to 50 μM in
the initial screening. An overview of the growth-reducing
activities of the six different substance collections is shown
in Figure 2 and in Table 1. The threshold for active com-
pounds was defined at a minimum growth reduction ofd 384-well MTP (B) in the presence of test compounds and controls.
compounds, 12 G-H: sterile medium. (B): 23 A-D and 24 A-D: 1% DMSO,
f compounds, 23 M-P and 24 M-P: sterile medium. Upper panels:
ed in red indicate active compounds.
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Figure 2 Screening results. Summary of the initial screening results for novel antibacterial compounds. The tested compounds came from the
NCH, Peptide, LOPAC, VAR, EMC and CDI collections. The shaded area highlights the activities that were defined as initial hits. The most active
compound, vz0825, stemming from the VAR collection, is highlighted in red.
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in a suitable initial hit rate. The smallest of the six collec-
tions, the NCH collection of 154 compounds, showed the
most active molecules with 32.5 hits per 1,000 substances.
Several of these molecules displayed antibacterial activities
that have been known before [7]. The VAR library consists
of molecules with predominantly unexplored activities and
contained 8.8 antibacterial compounds per 1,000 molecules.
With 17 hits this collection contained the highest number
of antibacterial molecules in total.
In total 42 hits were identified in the initial screening
campaign. These initial hits were reevaluated in differ-
ent concentrations by using V. cholerae strains and
several other Gram-positive and Gram-negative patho-
genic bacteria. After these reevaluations, the number
of active compounds was reduced to three most prom-
ising agents with the designations vz0825, vz0500 and
1541–0004. The former two compounds are derived
from the VAR library, the last one from the commer-
cially available CDI library. The chemical structures
are shown in Figure 3.Table 1 Summary of the screening for growth-reducing comp
Substance collection
(number of compounds)
Number of active compounds a
50-60% 60-70% 70-
NCH (154) 0 2
Peptide (1,045) 0 0
LOPAC (1,408) 2 4
VAR (1,936) 1 5
EMC (7,304) 1 0
CDI (16,608) 5 3
28,324MIC and MBC values of the most active substances
The two pathogenic V. cholerae O1 type stains N16961
and NM06-058 were used to determine the MIC and
MBC values for the compounds vz0825, vz0500 and
1541–0004 (Table 2). V. cholerae N16961 belongs to bio-
type El Tor which caused the seventh pandemic [8] and
was isolated in 1971. V. cholerae NM06-058 was isolated
in 2006 in Kolkata from a cholera patient and represents
the altered El Tor biotype. The active compounds inhib-
ited growth of both strains equipotent at low micromolar
concentrations with MIC values of 1.6 μM, 3.1 μM and
6.3 μM, respectively. In order to obtain reliable data, bac-
tericidal activities were determined after 2, 6 and 24 hours.
All three compounds killed the bacteria at low micromolar
concentrations, only slightly above the respective MIC
values (Table 2). Further nine V. cholerae strains belonging
to the O1, O139 and non O1/O139 serogroups (Table 3)
(three strains of each serogroup) were testes with com-
pound vz0825, which is active against all tested strains
with MIC values between 0.4 and 3.1 μM. Overall vz0825
was the most active substance.ounds
t different growth reduction rates ∑ Hit
rate/1,00080% 80-90% 90-100%
1 2 0 5 32.5
0 0 0 0 0
0 0 0 6 4.3
2 8 1 17 8.8
0 0 0 1 0.1
5 0 0 13 0.8
42 1.6
vz0825 vz0500 1541-0004 
A B C
Figure 3 Chemical structures. Most active compounds of V. cholerae growth inhibition. Panel A: compound vz0825; Panel B: compound vz0500;
Panel C: compound 1541-0004.
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was investigated with different Gram-positive and
Gram-negative pathogenic bacteria, which are able to
induce serious gastrointestinal infections in humans
(Table 4). Apparently, the antimicrobial activity of the
three substances was limited to V. cholerae, only com-
pound 1541–0004 also displayed a moderate activity
against S. aureus with an MIC of 6.3 μM.
Cytotoxicity determination via MTT-assay
In vitro cytotoxicity determination by MTT test with
mammalian cells is one of the standard procedures for
the evaluation of new active agents [10]. The well estab-
lished assay was carried out with the permanent mouse
fibroblast cell line L929 according to a published pro-
cedure [11] with some modifications [12]. In the assay
cell viability is determined by the reduction of the yel-
low MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenylte-
trazoliumbromid) to the violet formazan by the action
of ER- and mitochondrial enzymes. Concentrations of
the active compounds vz0825, vz0500 and 1541–0004
from 0.003 to 370 μM were used and effects on the fi-
broblasts were analyzed after 24 hours and 5 days of
incubation. The IC50 values are shown in Table 5. TheTable 2 MIC and MBC values for the most active
compounds against V. cholerae
Concentration [μM]
V. cholerae strain Incubation
time
vz0825 vz0500 1541-0004
N16961 MIC 24 h 1.6 3.1 6.3
MBC 2 h 50 50 50
6 h 12.5 6.3 6.3
24 h 6.3 6.3 6.3
NM06-058 MIC 24 h 1.6 3.1 6.3
MBC 2 h 50 50 6.3
6 h 12.5 6.3 6.3
24 h 1.6 6.3 6.3two most active compounds vz0825 and vz0500 showed
cytotoxic (inhibition after 24 hours of incubation) and
anti-proliferative (inhibition after 5 days of incubation)
IC50 values at low micromolar concentrations. Compound
1541–0004 is less cytotoxic, but has also a strong antipro-
liferative activity.
Generation of resistant mutants against vz0825
Mutants against vz0825 were generated by selection of
variants of the wild type strain NM06-058 that are able
to grow on agar plates containing 8 μM vz0825. After
one round of selection, 15 resistant mutants were picked
and analyzed individually. They displayed 4–16 fold re-
duced sensitivities (MIC 6.3 - 25 μM) against vz0825
compared to the wild type strain. In order to obtain an indi-
cation if vz0825 has a mode of action that is different from
standard antimicrobials, eight established antibiotics against
the major different antibacterial targets were tested with
the resistant mutants. The addressed targets and their in-
hibitors were i) cell wall synthesis (ampicillin), ii) protein
biosynthesis (tetracycline), iii) DNA-replication (ciprofloxa-
cin), iv) DNA-dependent RNA polymerase (rifampicin), v)
translation (chloramphenicol, erythromycin) and vi) synthe-
sis of folic-acid (trimethoprim/sulfamethoxazol).
The V. cholerae wild type strain NM06-058 and resistant
mutants did not show differences in their MIC values
against all tested antibiotics (data not shown), suggesting
that vz0825 has a mode of action that is different from the
classical antibiotics.
Target identification
This result initiated a further investigation of the mode of
action of vz0825 by the comparative genome sequence
analysis approach. The method makes use of whole gen-
ome sequence analysis of resistant mutants that were gen-
erated against an active compound and the comparison of
the genome of the wild type and the mutant strain [13].
The genomes of the 15 resistant V. cholerae mutants were
isolated, pooled and analyzed via paired-end sequencing.
In parallel, the genome of the wild type strain from which
Table 3 Strains, cells, plasmids and primers used for this study
Strain, cell, plasmid, primer Relevant description/sequence Reference or source
Strains
V. cholerae
MO10 pG13 O139 containing pG13 This study
N16961 Wild type, O1, El Tor, Inaba Makassar (1971), clinical isolate [8]
NM06-058 Wild type, O1, El Tor, Ogawa Kolkata (1996), clinical isolate
NM06-058 T283M Contains a point mutation in gene
VC_A0531 on AA position 283
This study
RKI-ZBS2-A310-3 Isolate, O1, El Tor, Inaba RKI
RKI-ZBS2-A310-12 Isolate, O1, El Tor, Ogawa RKI
RKI-ZBS2-A198-1 Isolate, O1, El Tor, Ogawa RKI
RKI-ZBS2-A310-25 Isolate, O139, El Tor RKI
RKI-ZBS2-A186-9 Isolate, O139, El Tor RKI
RKI-ZBS2-186-10 Isolate, O139, El Tor RKI
RKI-ZBS2-A220-1 Isolate, Non O1/O139 RKI
RKI-ZBS2-A222-1 Isolate, Non O1/O139 RKI
RKI-ZBS2-A227-1 Isolate, Non O1/O139 RKI
Gram-negative
Acinetobacter baumannii ATCC 30007 DSMZ
E. coli ESBL, 5044257621-1 HZI
E. coli ETEC NICED
E. coli S17-1 HZI
Klebsiella pneumoniae 50219455 HZI
Pseudomonas aeruginosa 90013687 HZI
Salmonella typhimurium NICED
Shigella boydii NICED
Shigella flexneri NICED
Gram-positive
Enterococcus faecalis ATCC 20212 HZI
Staphylococcus aureus MRSA, N315 HZI
Cell line
L929 Mouse fibroblastic cell line Derived from commercial source, DSMZ: ACC 2
Plasmid
pG13 Plasmid containing the constitutive expressing
G13 promoter- and gfp-gene sequence,
ligated in pFPV27 vector, (Kmr)
[9]
pEX18Ap Plasmid containing Ampr gene β-lactamase,
the sacB gene encoding the levansucrase
HZI
Oligonucleotide primer
VC_A0531_forw2 TCACGAACCAACAGGATTAAG Used for colony PCR and sequencing of the products
VC_A0531_rev2 CGGTTAAAGTGGTAGCAGAG Same as above
Mut_forw_1 ACATCATCTAGAGCAGCAGCAACACAAGA (XbaI) Used for generation of the point mutation
Mut_rev_1 ATCGCGCCAAGCGGCATTTTTAGATCG Same as above
Mut_forw_2 CGATCTAAAAATGCCGCTTGGCGCGAT Same as above
Mut_rev_2 ACATCAAAGCTTAACATGCGCCACCAGAC (HindIII) Same as above
kdpD_del_forw_1 ACATCATCTAGAGGAATCCATCAAAGAAA (XbaI) Used for generation of the deletion mutation of kdpD
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Table 3 Strains, cells, plasmids and primers used for this study (Continued)
kdpD_del_rev_1 ACAGGATTAAGAAGCAATGAACAGTGAAATTAAGATCCTC Same as above
kdpD_del_forw_2 GAGGATCTTAATTTCACTGTTCATTGCTTCTTAATCCTGT Same as above
kdpD_del_rev_2 ACATCACTGCAGAACACAAGATCCAACAC (PstI) Same as above
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quenced by the same method. The alignment and annota-
tion of both probes was based on the published genome of
V. cholerae strain N16961 (chromosome 1: AE003852,
chromosome 2: AE003853 in NCBI) [14]. As shown in
Table 6, approximately 98% and 94% of the fragments
from the mutant-pool and the wild type, respectively,
could be aligned. The alignment was carried out via the
application of CLC Genomics Workbench V. 4.7.2 soft-
ware. The algorithm to search for crucial distinctions were
parameters like single nucleotide polymorphism (SNP)
and deletion and insertion polymorphism (DIP), where
one nucleotide was affected with a minimal mutation fre-
quency of 30%.
Under those conditions, the comparison of the wild type
and the pooled sequences from the mutants showed only
one significant mutation, this was located at position 848
in gene VC_A0531 and was present in about 30% (pre-
cisely 29.1%) of the sequenced fragments. These mutants
have the nucleobase thymine instead of cytosine on pos-
ition 848. The point mutation of this nucleobase leads to
an exchange of threonine to methionine on position 283
(T283M) of the expressed protein.
The gene VC_A0531 (GenBank: AE003853.1) is located
on the small chromosome of V. cholerae and encodes a
sensor histidine kinase, which is the homologous to KdpD
of E. coli and is responsible for osmotic potassium regula-
tion in the bacterial cell [15]. In addition to the wholeTable 4 MIC values of active compounds for different
pathogenic bacteria
MIC [μM]
Bacterial strain vz0825 vz0500 1541-0004
Gram-negative
Acinetobacter baumannii 50 > > 100 > 100
Escherichia coli, ESBL > 100 > > 100 > 100
Escherichia coli, ETEC > > 50 > > 50 > 50
Klebsiella pneumoniae 100 > 100 100
Pseudomonas aeruginosa > > 100 > > 100 > > 100
Salmonella typhimurium > > 50 > > 50 > > 50
Shigella boydii > > 50 > > 50 > 50
Shigella flexneri > > 50 > > 50 > 50
Gram-positive
Enterococcus faecalis 50 > > 100 > 100
Staphylococcus aureus, MRSA 50 100 6.3genome pool sequencing, the gene VC_A0531 (kdpD) of
the 15 mutants was analyzed individually by PCR amplifi-
cation. 4 of the 15 mutants, corresponding to 26.7%, had
the same mutation on reference position 848 of the gene
kdpD that was identified in the whole genome pool se-
quencing. Another four of the mutants showed point mu-
tations at other positions of the kdpD gene (Table 7).
Sensitivity of strain NM06-058 T283M against vz0825
A strain containing the point mutation T283M in the
kdpD gene was generated by site-directed mutagenesis.
Successful cloning was verified by a PCR amplification of
the affected gene and the sequencing of the fragment. The
mutant was selected on LB-agar plates containing vz0825
at 16 μM concentration, which is 10-times higher than the
MIC of the wild type strain. A growth analysis with this
strain was carried out in vz0825 supplemented LB-
medium and in T-medium with different potassium and
sodium ion concentrations (Figure 4). Overall, growth of
the T283M mutant was much less effected by vz0825 in
comparison to the wild type strain. Sensitivity of the
T283M mutant against compounds vz0500 and 1541–
0004 did not differ from the wild type strain NM06-058
(data not shown).
Attempts to construct a kdpD knockout mutant
For a further elucidation of the effect of vz0825, the con-
struction of a V. cholerae kdpD knockout mutant was
attempted. If KdpD is a major target of compound vz0825,
the V. cholerae kdpD knockout mutant should be insensi-
tive to the compound, unless the protein itself and its
function are essential for the viability of the bacteria. The
cloning procedure delivered the expected plasmid con-
struct according to sequencing. The plasmid was success-
fully transformed into the E. coli strain S17-1, according
to the acquirement of ampicillin resistance, which is lo-
cated on the plasmid pEX18Ap and also according to PCR
amplification of the construct. The conjugation of theTable 5 Cytotoxic (24 h) and antiproliferative (5 d)
activity of the most active compounds according to MTT
test with L929 cells
Compound IC50 [μM]
24 h 5 d
vz0825 14 6
vz0500 3 1
1541-0004 170 14
Table 6 Summarized statistics of genome sequencing
Number of
fragments
Average
length [bp]
Total base
number
wt genome
Fragments 11,260,864 76 855,825,664
Identified 10,574,557 (93.9%) 76 803,666,332
Non-identified 686,307 (6.1%) 76 52,159,332
Genome-pool
Fragments 35,196,596 72.36 2,546,713,435
Identified 34,210,563 (97.8%) 72.43 2,477,950,102
Non-identified 986,033 (2.8%) 69.74 68,763,333
Reference 2 2,016,732 4,033,460
Reference genome came from V. cholerae strain N16961 [14].
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lection on LB agar plates supplemented with carbenicillin
(Carb) and Km did not lead to clones with a deleted
VC_A0531 gene, even after several modifications of the
protocol. A possible explanation is that the gene product
KdpD is indeed essential for V. cholerae, in agreement
with KdpD being a prime target of vz0825.
Discussion
A HTS assay for small molecule inhibitors of V. cholerae
was developed and validated using a viability phenotype of
V. cholerae that constitutively expresses green fluores-
cence. The assay is reliable, reproducible and simple to
perform. During the development of the reporter strain,
two reference strains of O1 serogroup belonging to bio-
types O395 (classical) and N16961 (El Tor) were included
along with the O139 strain MO10. The green fluorescence
producing plasmid pG13 was electroporated into the three
strains. During initial standardization experiments it was
observed that the strain MO10 pG13 produced much
greater level of green fluorescence as compared to other
two strains (data not shown). For this reason strain MO10
pG13 was used in the screening experiments.
A data bank search in SciFinder for the most active
compounds vz0825 and vz0500 did not reveal pre-
described antibacterial activities of the compounds with
structural similarities above 70%. Compound 1541–0004,
stemming from the commercial CDI collection, belongs to
the group of styryl dyes, which have already in 1966 beenTable 7 Modifications detected in gene VC_A0531 (kdpD) by
Nucleotide pos. Ref. allel Mut. allel Number of mutant
1 218 T C 1
2 848 C T 4
3 1,022 C A 1
4 1,177 G A 1
5 1,178 A G 1
In bold the major statistically significant mutation is highlighted.shown to possess antimicrobial effects against the plant
pathogen Xanthomonas oryza [16]. The IC50 value for
acute cytotoxicity of compound vz0825 in an MTT test
was approximately 17-times higher than its MIC value.
For vz0500, both IC50 and MIC values were about equal.
For compound 1541–0004 the IC50 value for cytotoxicity
was approximately 27-times higher than the MIC value.
Although the identified compounds exhibited antimicro-
bial activities at low concentrations, the toxicities render
them unsuitable for direct clinical application. Thus, the
compounds may serve as pharmaceutical leads and modi-
fications via the methods of medicinal chemistry may lead
to better properties.
The elucidation of the mode of action of new antimi-
crobials can be a tedious and time consuming effort and
can require the application of a variety of biochemical
and molecular methods [17,18]. Due to the advances in
genome sequencing instrumentation and methodology,
an innovative new option has become available recently.
It employs genomic sequence comparison of resistant
mutants with wild type strains and has been successfully
applied for target identification in a limited number of
previous investigations by other researchers [13]. As we
have used NM06-058 for the evaluation of the active
compounds, we have used the same strain to create re-
sistant mutants against vz0825. The V. cholerae strain
NM06-058 was isolated from hospitalized diarrhea cases
during 2006 at Kolkata, India. This strain along with other
V. cholerae strains isolated during 2006 was studied for the
expression of cholera toxin (CT) and it was identified that
NM06-058 is capable of producing a higher amount of CT
in vitro compared to other strains and to reference V. cho-
lerae O1 El Tor strain N16961. Based on the high virulence
expression, this strain was selected for our investigations.
Clinical V. cholerae O1 strains isolated at Kolkata during
and after 1995 belonged to altered El Tor biotypes [19].
Thus it can be considered that strain NM06-058 represents
the altered V. cholerae El Tor biotype, which is still the pre-
vailing type among cholera cases.
The generation of mutants that were resistant against
vz0825 was straightforward in this study by plating the
wild type strain on agar plates containing the active com-
pound at 5-times the MIC value of the wild type. The suc-
cessful generation of resistant mutants with only onePCR analysis of 15 resistant mutants (AA, amino acid)
s Codon old Codon new AA pos. AA old AA new
CUA CCA 73 Leu Pro
ACG AUG 283 Thr Met
CCU CAU 341 Pro His
GAA AAA 393 Glu Lys
GAA GGA 393 Glu Gly
A B
502512.56.33.11.60.80
ab
so
rb
an
ce
 a
t 6
00
 n
m
concentration [µM]
NM06-058 wild type
502512.56.33.11.60.80
ab
so
rb
an
ce
 a
t 6
00
 n
m
concentration [µM]
NM06-058 T283M
0.4
0.3
0.2
0.1
0
0.4
0.3
0.2
0.1
0
Figure 4 Growth determination. Growth of V. cholerae wild type strain NM06-058 (A) and the T283M exchange mutant (B) in the presence of
vz0825 in media with different K+ and Na+ concentrations.
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vz0825. The aligned sequences of the wild type genome
and the mutant genome pool were compared with each
other. For the identification of significant mutations the
minimal frequency in the mutant genome pool was de-
fined at 30%. A lower frequency would deliver too many
non-relevant mutations. In the genome pool of the 15 re-
sistant mutants only the gene with the code number
VC_A0531, which corresponds to the homologue kdpD in
E.coli, showed a significant mutation under the chosen pa-
rameters with frequency of 29.1%. The sequencing of the
15 resistant mutants showed, that 4 of them (26.7%) pos-
sess this particular modification. The mutated nucleobase
is the second base of the corresponding codon and causes
an exchange of the amino acid threonin by methionine in
the expressed protein. Another four mutants also possess
point mutations at other positions of the gene (shown in
Figure 5). All of those mutations lead to an exchange of
one particular amino acid in the expressed protein, two of
them which are located in the N-region (position 1,177
and 1,178) lead to the exchange of glutamic acid 393 to ly-
sine or glycin, respectively (Table 7 and Figure 5). Thus, 8
of 15 mutants possess a mutation in the kdpD gene.
A comparison of known protein domains in the data-
base Pfam Protein Families [21] resulted in the localization
of the affected amino acid in the dimerization/phosphor
acceptor domain. Histidine kinase dimers are formed by
parallel association of two domains creating 4-helix bun-
dles; usually these domains contain a conserved histidine
residue and are activated via trans-autophosphorylation by
the catalytic domain [22]. They subsequently transfer the
phosphoryl group to the aspartic acid acceptor residue of
a response regulator protein. Based on the comparison of
conserved regions in a number of bacterial histidine ki-
nases [20], the localization could be specified moreprecisely between the H–region and the N-region (Figure 5).
The H-region is the most variable sequence of histidine ki-
nases in bacteria and contains the histidine that is phos-
phorylated in the signal transduction process. The N-region
shuttles the gamma-phosphate from ATP to the histidine
residue. The mutated amino acid is localized between the
conserved H- and N-region (Figure 5) and thus in a part of
the protein that shows high interspecies variation [23],
which could explain the specificity of vz0825 against V.
cholerae.
In the two-component system of signal transduction,
the histidine kinase transfers the signal to a response
regulator. The V. cholerae protein VC_A0531 is the
homolog of KdpD in E. coli, the response regulator of
which is KdpE [24]. The signal transduction system
KdpABC, regulated by KdpD and KdpE, is part of the
osmoregulation machinery in bacteria [15]. Compound
vz0825 may exert its mode of action by binding to the
histidine kinase KdpD and thereby inhibiting signal
transduction. This would lead to a deficient uptake of
potassium. If this mechanism leads to the observed re-
duction of bacterial viability remains to be elucidated.
Due to a lack of specific information about the potas-
sium regulation in V. cholerae, we compared our findings
with results that have been obtained with E. coli. E. coli
possesses in addition to the KdpABC potassium regulatory
system several further K+ dependent signal transduction
systems. The K+ regulatory systems Trk and Kup are ac-
tive at physiological K+ concentrations [15]. The expres-
sion of KdpD and consequently of the KdpABC system
in E. coli is induced at low potassium concentrations
(<60 mM) [25]. In E. coli KdpD is not essential at a potas-
sium concentration >115 mM, as mutants with truncated
forms of KdpD are viable under these conditions, but in
media with <15 mM K+ those strains do not grow [25]. V.
Figure 5 Sequence of KdpD from V. cholerae. Amino acids labeled in green in the regions H, N, G1, F, G2 are conserved in different species
[20]. Labeled in red is threonine 283 which is exchanged by methionine in the dominant mutations of the resistant strains. Amino acids labeled
in blue indicate the positions that are modified in four additional mutants (L73P, P341H, E393K and E393G).
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systems for the adaptation to changing osmotic conditions
[26,27].
The V. cholerae mutant strain T283M grows well in
media with high and low K+ and Na+ concentrations in
absence of vz0825 as shown in Figure 4. Even at 4 mM K+
growth is not diminished. This figure also shows the dif-
ference between the tolerance of the wild type and the
T283M strain against vz0825. Our findings that T283M
grows well in K+ reduced medium indicates that the inhib-
ition of KdpD may have profound influence on some
other, hitherto undefined, regulatory function of this pro-
tein in V. cholerae. The influence of vz0825 on KdpD may
appear in different ways, e.g. reducing the binding of ATP
to the histidine kinase, inhibiting the transfer of gamma-
phosphate to the histidine residue, or to the asparagine
residue of the response regulator. Like other histidine ki-
nases KdpD also has phosphatase activity [28], which may
be disturbed by vz0825. The mutated amino acid on pos-
ition 283 is located between the H-region and N-region.
Mutations that alter this motif, which is termed the X-
region, have been shown to alter the conformation of the
histidine kinase EnvZ and significantly reduce its phosphat-
ase activity [29]. EnvZ is a membrane receptor kinase-
phosphatase, which modulates porin expression in E. coli in
response to medium osmolarity. It shares its basic scheme
of signal transduction with many other sensor-kinases [29].
If KdpD is the major target of compound vz0825, the
deletion construct ΔkdpD should be insensitive to the sub-
stance in media with physiological K+ concentration –
provided that it is still viable. The construction of the
required plasmid for the generation of this construct, its
transformation into E. coli S17-1 and the conjugation from
E. coli into V. cholerae were successful in this study, but
several attempts to induce the homolog recombinationwithin V. cholerae NM06-058 failed. None of the analyzed
clones showed a loss of the kdpD gene. The apparent
growth reducing effect of vz0825 and its targeting of
KdpD in V. cholerae suggests a more important role of
KdpD in V. cholerae than in E. coli. Further experiments
are required in order to corroborate the effect of vz0825
on KdpD, like functional assays with the expressed pro-
tein, in which the kinase- and phosphatase activities of the
wild type and mutated forms in the presence of vz0825
are compared. It would also be desirable to carry out ex-
pression profiling of the transcriptome of vz0825 sensitive
and resistant V. cholerae strains. This procedure could
help to determine how relevant the expression of kdpD in
V. cholerae is and whether the expression of other genes is
reduced or induced in the resistant strains.
Conclusions
In a high-troughput screening assay with 28,300 com-
pounds the synthetic small molecule vz0825 was identified
as the most active antibacterial substance against V. cho-
lerae with an MIC of 1.6 μM and an MBC of 3.2 μM.
Whole genome sequencing was carried out with resistant
mutants and the two-component histidine kinase KdpD
was identified as the prime target of the substance. Further
investigations should address the inhibitory mechanism in
more detail and corroborate on the possibility of an essen-
tial function of KdpD in V. cholerae. Histidine kinase in-
hibitors are in principal promising antimicrobial drug
candidates [30] and compounds like vz0825 may lead to
new treatment options.
Methods
Strains, media and plasmids
The strains used in this study are listed in Table 3. Re-
porter strain MO10 pG13 was generated from the
Sergeev et al. BMC Microbiology 2014, 14:49 Page 10 of 13
http://www.biomedcentral.com/1471-2180/14/49pathogenic wild type strain MO10, serogroup O139,
which was electroporated with the plasmid construct
pG13 containing a kanamycin resistance gene (Kmr)
and was selected on a plate containing 30 μg/ml Km. V.
cholerae strains were grown in LB medium (pH 7.0) at
37°C. LB medium containing Km (30 μg/ml) was used for
HTS and Cip (100 μM) was used for positive control. To
determine the MIC and MBC values, Mueller-Hinton
(MH) broth (pH 7.4) was used as growth medium. Suscep-
tibility to ampicillin (Amp), tetracycline (Tet), Cip, rifampi-
cin, chloramphenicol, erythromycin, sulfamethoxazole, and
trimethoprim/sulfamethoxazole (SXT) was determined in
96-well MTP containing MH medium supplemented with
varied amounts (1 to 1,024 μg/ml) of each antibiotic separ-
ately and varied amounts of SXT (0.13/2.38 to 8/152 μg/
ml). Supplemented LB medium with Amp (50 μg/ml), Km
(30 μg/ml) and Carb (100 μg/ml) was used during the pro-
cedures of site-directed mutagenesis and in T medium
pH 7.4. T medium was prepared by adding 17 g tryptone,
3 g neutralized soy peptone, 10 g glucose, 50 mM MOPS,
100 mM NaCl, 2 mM KCl and 2 mM CaCl2 in 1 l of water.
For homolog recombination NaCl-free (for increased su-
crose sensitivity [31]) LB medium or T medium with 10%
sucrose (for induction of pEX18Ap plasmid excision, carry-
ing the sacB gene) was used. Cultivation of the mouse
fibroblas cell line L292 was carried out in DMEM with 10%
FBS (Lonza).
Substance collections
Three commercially available substance collections were
used in the screening campaigns: i) the LOPAC collection
of pharmacologically active compounds with 1,408 entities
(Sigma-Aldrich); ii) the Echaz Microcollection with 7,304
compounds (EMC Microcollections GmbH, Tübingen,
Germany); and iii) the CDI collection with approximately
17,000 compounds (Chemical Diversity Lab, Inc., San
Diego, USA), this commercially available collection has
been assembled by members of the ChemBioNet consor-
tium [32]. Three additional libraries that were used are
unique at the HZI: iv) the NCH collection consisting of 154
secondary metabolites from myxobacteria [33]; v) the li-
brary Various Sources (VAR) contained at the time of this
study 1,936 synthetic organic molecules that were provided
by various collaborators; and vi) the Peptide library con-
tained 1,045 short linear or cyclic peptide sequences syn-
thesized at the HZI [6]. All test compounds were utilized as
stock solutions in DMSO.
Growth assay
50 μl or 25 μl of LB-Km medium were inoculated in clear
flat-bottom 96-well or 384-well MTP, respectively. Test
compounds were added from DMSO stocks in amounts
that resulted in assay concentrations between 20 and
50 μM. 50 μl or 25 μl of bacterial culture in LB-Kmmedium with an absorbance of 0.2 at 600 nm (OD600)
(Ultraspec 2100 Pro photometer, Pharmacia, GE Health-
care, Chalfont St Giles, UK) were added to the 96-well or
384-well MTP, respectively. The seeding of bacteria and
addition of the compounds was carried out with the pipet-
ting system Evolution P3 (PerkinElmer, Waltham, USA).
Stationary incubation of the plates for 24 h at 37°C under
moist conditions was carried out, followed by determination
of absorbance at 600 nm and fluorescence at 485/535 nm
(Fusion Universal Microplate Analyzer, PerkinElmer,
Waltham, USA). As negative and positive controls DMSO
(1%) and Cip (100 μM) were used, respectively. During the
initial screening, approximately 28,300 compounds were
investigated with single determinations. Compounds that
reduced bacterial growth by at least 50% were retested
in a second campaign and the most active substances
were reevaluated at different concentrations between
0.1 and 100 μM.
MIC and MBC values determination
The determination of MIC and MBC values was carried
out with V. cholerae wild type strains and several Gram-
negative and Gram-positive bacteria (Table 3) following
standardized protocol [34] in broth dilution assays. Start-
ing inocula of 2-8×105 colony forming units/ml (CFU/ml)
in MH medium at 37°C were used and serial dilutions
were carried out in 96-well MTP in duplicate. At 2, 6 and
24 h of incubation, 10 μl of the cultures were plated on LB
agar plates. After an incubation of the plates for 24 h at
37°C, CFU/ml were determined and used for the deter-
mination of MBC, which is defined as minimum concen-
tration of the substance required for 99.9% reduction of
CFU after an incubation period of 6 h. The 2 h and 24 h
measurements were used for additional correlation. MIC
values were determined after 24 h of incubation.
Cytotoxicity assay
The mammalian cell line L929 was utilized to investigate
the cytotoxicity of the active compounds in a MTT assay
according to a modified protocol of Mosmann [11,12]. Fol-
lowing 24 h of incubation, acute toxicity was determined
based on the extent of cell viability and after incubation for
5 d mainly the inhibition of cell proliferation and subacute
toxicity were measured (absorption at 595 nm) (Wallac
Victor 1420 Multilabel counter, PerkinElmer, Waltham,
USA). IC50 is the concentration that reduces the viability of
the cells by 50%.
Generation of resistant mutants against vz0825
The protocol for the generation of resistant mutants was
the same as used in the publication of Bielecki et al. [13]. V.
cholerae strain NM06-058 was plated at a cell number of
1 × 109 CFU on LB agar plates containing 8 μM vz0825 (5-
times the MIC value). After incubation for 24 h at 37°C,
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preserved as mutants against vz0825.
Isolation of genomic DNA and sequencing of
genome-pool
Isolation of the genomic DNA was performed according
to the protocol of the DNeasy Blood and Tissue Kit
(Qiagen). Briefly, the 15 resistant mutants were inocu-
lated individually in 5 ml LB medium and incubated for
6 h at 37°C with shaking at 180 rpm. In parallel, the wild
type strain was cultivated under identical conditions.
Based on the OD600 measurements of the cultures, the
15 mutants were pooled in equal amounts. After adjust-
ing the cell number at 2 × 109 CFU the pooled mutants
and the wild type strain were collected by centrifugation.
The cell pellets were lysed by addition of ATL buffer
and proteinase K for 1 h at 56°C. RNA was removed by
addition of 4 μl RNase A (100 mg/ml) and incubation
for 2 min at RT. 200 μl AL buffer and afterwards 200 μl
of ethanol were added with mixing. The mixture was
transferred to DNeasy Mini spin columns and centri-
fuged at ≥ 6.000 × g for 1 min. Washing was carried out
with 500 μl AW1 buffer followed by centrifugation for
1 min. A second washing step was carried out with
500 μl AW2 buffer. The tubes were centrifuged for
3 min at 20,000 × g and the genomic DNA was eluted
from the membranes with 200 μl AE buffer.
Whole genome sequencing, alignment and annotation
were carried out in the sequencing facility of the HZI (head
Dr. Robert Geffers). Libraries of DNA fragments with an
average length of 300 bp were prepared according the man-
ufacturer’s instructions “Preparing Samples for Sequencing
Genomic DNA” (Illumina). Sequencing was carried out
with the Illumina Cluster Station and the Genome Analyzer
IIx. The resulting data was transformed into FastQ-format.
Sequencing of the DNA library resulted in a total base
count of 855,825,664 and 2,546,713,435 for wild type and
resistant mutants genome pool, respectively. This corre-
sponds to a calculated average coverage of 214 for the wild
type and for each resistant mutant to a coverage of 42. The
published complete genome has a total base number of
4,033,460 (Table 6, [14]).
The sequencing procedure resulted in 11,260,862 and
35,196,596 reads for wild type and resistant mutants gen-
ome pools, respectively, which were mapped to the refer-
ence genome of the annotated V. cholerae strain N16961
[14] by the application of the Read Mapper Tool and the
Probabilistic Variant Caller as part of CLC Genomics
Workbench V. 4.7.2 software. The Read Mapper Tool maps
reads and calculates average coverage at single nucleotide
resolution. The Probabilistic Variant Caller identifies vari-
ants by using a probabilistic model built from read mapping
data. Based on a combination of a Bayesian model and a
Maximum Likelihood approach the algorithm calculatesprior and error probabilities for the Bayesian model. By
using the Probabilistic Variant Caller software and defining
various parameters, such as sequence frequency, size of
mutated areas and mutation abundance, lists of SNPs and
DIPs were created. A frequency of more than 30 reads was
required for all fragments. The maximum number of allel-
variations was restricted to two, and the threshold of the
frequency of the allel-variations was set at a minimum of
30%. These lists were compared for the wild type strain and
the pooled resistant mutants, and SNPs that are unique for
the mutants were identified.
Colony PCR and sequencing
The 15 resistant mutants were analyzed individually to de-
termine whether they carry the point mutation on position
848 of the kdpD gene. Individual colonies were heated in
36.5 μl of water for 5 min at 95°C. 1 μl of dNTPs (stock so-
lution 10 mM), 2.5 μl of primers VC_A0531_forw2 and
VC_A0531_rev2 (stock solution 100 pmol/μl), 5 μl 10×
PCR buffer and 2.5 μl RED Taq polymerase (1 U/μl) were
added. After the PCR procedure, the products had the ex-
pected size of 915 bp. They were purified and sequenced in
the sequencing facility of the HZI using the above primers.
Construction of the point-mutant KdpD T283M in strain
NM06-058
The gene VC_A0531 has a size of 1,494 base pairs (cod-
ing for 497 amino acids plus stop codon). The base cyto-
sine, which was changed to tyrosine in the predominant
resistant mutants, is located on position 848. Site-
directed mutagenesis was used for the incorporation of
this modification into the wild type strain NM06-058.
Two overlapping amplicons with a size of 525 and
616 bp were generated from the gene of the wild type
strain NM06-058. Fragment one was amplified using the
primer pair (i) Mut_forw_1/Mut_rev_1, and the second
fragment was amplified with primer pair (ii) Mut_-
forw_2/Mut_rev_2. The primers Mut_rev_1 and Mut_-
forw_2 carried the point-mutation (Table 3, bold
nucleobases). Primers Mut_forw_1 and Mut_rev_2 con-
tained specific recognition nucleotide sequences for the
restriction enzymes XbaI and HindIII. Both amplicons
were mixed at equimolar ratio and a re-PCR was per-
formed with the primers Mut_forw_1 and Mut_rev_2 to
generate an amplicon with a size of 1,114 bp. This
amplicon and the plasmid pEX18Ap were restricted with
XbaI and HindIII. Insert and plasmid were ligated and
transformed into chemically competent E. coli strain
S17-1. Amp (100 μg/ml) was incorporated into the agar
of the plate for selection of pEX18Ap containing trans-
formants. PCR based analysis of the transformants
followed by nucleotide sequencing analysis confirmed
the proper insert into the vector, which was subse-
quently used for the conjugation assay.
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with a bacterial proportion of 4:1 of E. coli containing con-
jugative plasmid (donor) and V. cholerae as recipient
strain. Bacterial cultures (mixed E. coli and V. cholerae)
were plated on LB agar plate containing Carb (100 μg/ml)
and Km (30 μg/ml) for selection of V. cholerae transconju-
gants carrying the plasmid. The removal of vector back-
bone from V. cholerae genome was achieved by favoring
the homologous recombination and use of lethal sacB
gene while passaging the transconjugants in sodium chlor-
ide free LB medium supplemented with 10% sucrose.
Attempts for construction of a kdpD knockout mutant
using V. cholerae strain NM06-058
The gene VC_A0531 encodes for the histidine kinase
KdpD in V. cholerae and is flanked by the genes
VC_A0530 encoding pyruvate-flavoredoxin oxidoreduc-
tase and VC_A0532 encoding response regulator KdpE
homologue of E. coli. To generate a VC_A0531 deletion
mutant, two fragments were amplified from the small
chromosome of the wild type strain NM06-058 using
two primer pairs (i) kdpD_del_forw_1 / kdpD_del_rev_1
and (ii) kdpD_del_forw_2 / kdpD_del_rev_2. Using the
first primer pair an approximately 600 pb fragment of
gene VC_A0530 was amplified with a 24 bp homolog
overhang to the start region of the VC_A0532 at the C-
terminus. The second primer pair was used to amplify an
approximately 400 bp fragment of the gene VC_A0532
with a 16 bp overhang homolog to the end region of the
VC_A0530 at the N-terminus. Both amplicons were mixed
together at equimolar ratio and a re-PCR was carried out
with a combination of primers kdpD_del_forw_1 and
kdpD_del_rev_2 to generate an amplicon with a size of ap-
proximately 1,000 bp. The restriction of vector pEX18Ap
and the insert was carried out with XbaI and PstI. After
ligation and transformation into E. coli S17-1, a conjuga-
tion into the wild type V. cholerae strain NM06-058 was
mediated according to the protocol described above. The
cloning strategy was successful until transconjugation ac-
cording selection on Carb / Km agar plates and sequen-
cing, but homolog recombination attempts with V.
cholerae strain NM06-058 did not yield viable strains with
deleted kdpD gene.
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